Riskpilot← Back to searchSign inGet full accessMedokrin AB
ABActiveOrg 5591348072Stormhagsvägen 4General medical practice activities · NACE 8621Est. 20171 employees
Revenue 2024
SEK 319K
-26% vs 2023
EBITDA margin
66.3%
-37% vs 2023
Equity ratio
57.0%
Financial strength
Net profit 2024
SEK 225K
+14% vs 2023
| Revenue | SEK 319K | -26% |
| EBITDA | SEK 211K | -37% |
| Net profit | SEK 225K | +14% |
| Total assets | SEK 503K | -15% |
| Equity | SEK 287K | +9% |
| Employees | 1 | — |
Legal name
Medokrin AB
Org number
5591348072
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
22 november 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolagets verksamhet är läkartjänster, medicinsk rådgivning, jourverksamhet och beredskap, allmän läkarmottagning, primärvård och konsultverksamhet inom vård och medicin. Import av olivolja och honung och andra ekologiska livsmedel samt därmed förenlig verksamhet.
Address
Stormhagsvägen 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 104 | 319 | 249 | 432 | 319 |
| Staff expenses | — | — | −0 | −0 | −11 |
| EBITDA | 63 | 267 | 172 | 335 | 211 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 63 | 267 | 172 | 335 | 211 |
| Net financials | −1 | — | 0 | 1 | 0 |
| Profit before tax | 63 | 267 | 172 | 250 | 289 |
| Tax | −14 | −55 | −36 | −53 | −64 |
| Net profit | 49 | 212 | 137 | 197 | 225 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 336 | 478 | 406 | 590 | 503 |
| Equity | 105 | 317 | 266 | 263 | 287 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 154 | 85 | 63 | 165 | 130 |
| Total debt | 154 | 85 | 63 | 165 | 130 |
EBITDA margin
66.3%
This company
15.8%
Market median
+320% vs market
20202024
Equity ratio
57.0%
This company
38.2%
Market median
+49% vs market
20202024
Return on equity
78.2%
This company
18.4%
Market median
+325% vs market
20202024
Net profit margin
70.4%
This company
8.1%
Market median
+769% vs market
20202024
Asset turnover
0.63×
This company
1.12×
Market median
-44% vs market
20202024
Debt / equity
0.75×
This company
0.62×
Market median
+21% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medokrin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Apostolos Chaftas | Board of Directors | 0 companies |
| Panagiota Papadopoulou | Deputy Board Member | 0 companies |